Cargando…
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy
We assessed vaccine-induced antibody responses to the SARS-CoV-2 ancestral virus and Omicron variant before and after booster immunization in 57 patients with B cell malignancies. Over one-third of vaccinated patients at the pre-booster time point were seronegative, and these patients were predomina...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070099/ https://www.ncbi.nlm.nih.gov/pubmed/36749632 http://dx.doi.org/10.1172/jci.insight.163434 |
_version_ | 1785018964607238144 |
---|---|
author | Azar, Joseph H. Evans, John P. Sikorski, Madison H. Chakravarthy, Karthik B. McKenney, Selah Carmody, Ian Zeng, Cong Teodorescu, Rachael Song, No-Joon Hamon, Jamie L. Bucci, Donna Velegraki, Maria Bolyard, Chelsea Weller, Kevin P. Reisinger, Sarah A. Bhat, Seema A. Maddocks, Kami J. Denlinger, Nathan Epperla, Narendranath Gumina, Richard J. Vlasova, Anastasia N. Oltz, Eugene M. Saif, Linda J. Chung, Dongjun Woyach, Jennifer A. Shields, Peter G. Liu, Shan-Lu Li, Zihai Rubinstein, Mark P. |
author_facet | Azar, Joseph H. Evans, John P. Sikorski, Madison H. Chakravarthy, Karthik B. McKenney, Selah Carmody, Ian Zeng, Cong Teodorescu, Rachael Song, No-Joon Hamon, Jamie L. Bucci, Donna Velegraki, Maria Bolyard, Chelsea Weller, Kevin P. Reisinger, Sarah A. Bhat, Seema A. Maddocks, Kami J. Denlinger, Nathan Epperla, Narendranath Gumina, Richard J. Vlasova, Anastasia N. Oltz, Eugene M. Saif, Linda J. Chung, Dongjun Woyach, Jennifer A. Shields, Peter G. Liu, Shan-Lu Li, Zihai Rubinstein, Mark P. |
author_sort | Azar, Joseph H. |
collection | PubMed |
description | We assessed vaccine-induced antibody responses to the SARS-CoV-2 ancestral virus and Omicron variant before and after booster immunization in 57 patients with B cell malignancies. Over one-third of vaccinated patients at the pre-booster time point were seronegative, and these patients were predominantly on active cancer therapies such as anti-CD20 monoclonal antibody. While booster immunization was able to induce detectable antibodies in a small fraction of seronegative patients, the overall booster benefit was disproportionately evident in patients already seropositive and not receiving active therapy. While ancestral virus– and Omicron variant–reactive antibody levels among individual patients were largely concordant, neutralizing antibodies against Omicron tended to be reduced. Interestingly, in all patients, including those unable to generate detectable antibodies against SARS-CoV-2 spike, we observed comparable levels of EBV- and influenza-reactive antibodies, demonstrating that B cell–targeting therapies primarily impair de novo but not preexisting antibody levels. These findings support rationale for vaccination before cancer treatment. |
format | Online Article Text |
id | pubmed-10070099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-100700992023-04-05 Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy Azar, Joseph H. Evans, John P. Sikorski, Madison H. Chakravarthy, Karthik B. McKenney, Selah Carmody, Ian Zeng, Cong Teodorescu, Rachael Song, No-Joon Hamon, Jamie L. Bucci, Donna Velegraki, Maria Bolyard, Chelsea Weller, Kevin P. Reisinger, Sarah A. Bhat, Seema A. Maddocks, Kami J. Denlinger, Nathan Epperla, Narendranath Gumina, Richard J. Vlasova, Anastasia N. Oltz, Eugene M. Saif, Linda J. Chung, Dongjun Woyach, Jennifer A. Shields, Peter G. Liu, Shan-Lu Li, Zihai Rubinstein, Mark P. JCI Insight Research Article We assessed vaccine-induced antibody responses to the SARS-CoV-2 ancestral virus and Omicron variant before and after booster immunization in 57 patients with B cell malignancies. Over one-third of vaccinated patients at the pre-booster time point were seronegative, and these patients were predominantly on active cancer therapies such as anti-CD20 monoclonal antibody. While booster immunization was able to induce detectable antibodies in a small fraction of seronegative patients, the overall booster benefit was disproportionately evident in patients already seropositive and not receiving active therapy. While ancestral virus– and Omicron variant–reactive antibody levels among individual patients were largely concordant, neutralizing antibodies against Omicron tended to be reduced. Interestingly, in all patients, including those unable to generate detectable antibodies against SARS-CoV-2 spike, we observed comparable levels of EBV- and influenza-reactive antibodies, demonstrating that B cell–targeting therapies primarily impair de novo but not preexisting antibody levels. These findings support rationale for vaccination before cancer treatment. American Society for Clinical Investigation 2023-03-22 /pmc/articles/PMC10070099/ /pubmed/36749632 http://dx.doi.org/10.1172/jci.insight.163434 Text en © 2023 Azar et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Azar, Joseph H. Evans, John P. Sikorski, Madison H. Chakravarthy, Karthik B. McKenney, Selah Carmody, Ian Zeng, Cong Teodorescu, Rachael Song, No-Joon Hamon, Jamie L. Bucci, Donna Velegraki, Maria Bolyard, Chelsea Weller, Kevin P. Reisinger, Sarah A. Bhat, Seema A. Maddocks, Kami J. Denlinger, Nathan Epperla, Narendranath Gumina, Richard J. Vlasova, Anastasia N. Oltz, Eugene M. Saif, Linda J. Chung, Dongjun Woyach, Jennifer A. Shields, Peter G. Liu, Shan-Lu Li, Zihai Rubinstein, Mark P. Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy |
title | Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy |
title_full | Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy |
title_fullStr | Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy |
title_full_unstemmed | Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy |
title_short | Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy |
title_sort | selective suppression of de novo sars-cov-2 vaccine antibody responses in patients with cancer on b cell–targeted therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070099/ https://www.ncbi.nlm.nih.gov/pubmed/36749632 http://dx.doi.org/10.1172/jci.insight.163434 |
work_keys_str_mv | AT azarjosephh selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT evansjohnp selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT sikorskimadisonh selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT chakravarthykarthikb selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT mckenneyselah selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT carmodyian selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT zengcong selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT teodorescurachael selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT songnojoon selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT hamonjamiel selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT buccidonna selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT velegrakimaria selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT bolyardchelsea selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT wellerkevinp selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT reisingersaraha selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT bhatseemaa selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT maddockskamij selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT denlingernathan selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT epperlanarendranath selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT guminarichardj selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT vlasovaanastasian selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT oltzeugenem selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT saiflindaj selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT chungdongjun selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT woyachjennifera selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT shieldspeterg selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT liushanlu selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT lizihai selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy AT rubinsteinmarkp selectivesuppressionofdenovosarscov2vaccineantibodyresponsesinpatientswithcanceronbcelltargetedtherapy |